Futu News, February 22, this Tuesday $LEPU BIO (02157.HK)$The announcement announced that the company will issue about 127 million shares, priced at HK$7.13 per share, 1,000 shares per lot, and is expected to go public on February 23.
During the public sale phase, Lepu Biotech received about 5.65 times more subscriptions. The final number of shares offered for sale was 12.688 million shares, accounting for about 10% of the total number of shares offered (before any over-allotment rights were exercised). A total of 6141 valid applications were received, with a first-hand winning rate of 22.31%, and a steady stream of 5 subscriptions.
Furthermore, the international offering was slightly oversubscribed (about 1.53 times), and the final number of shares offered was approximately 114 million shares, equivalent to about 90% of the total number of shares offered (before any overallotment rights were exercised). Futu Information collates the relevant data in the following table:
The net proceeds of approximately HK$804 million will be used for the following purposes: 68.5% for core products; 6.3% for other major clinical-stage drug candidates and major pre-clinical drug candidates; 15.8% for the acquisition of potential technology and assets and the expansion of the drug candidate pipeline, including the discovery of new drug candidates and business development activities, and fulfilment of the company's ongoing payment obligations under the acquisition of HX008 from Hans; 9.4% for general corporate purposes.
Lepu Biotech was founded in 2018 and is a biopharmaceutical company focusing on the field of cancer treatment. It has...